

Provided by:



Cardiovascular Surgery Morbidity & Mortality Case Conference 2025-2026

Cardiovascular Surgery Morbidity & Mortality Case Conference 2025-2026 - 7/17/2025

July 17, 2025

7:30 AM - 8:30 AM

Multipurpose Conference Rm on 2M

Target Audience

This program has been designed for THORACIC AND CARDIAC SURGERY

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe new trends and therapeutic modalities in surgery today.
- 1 Describe how to Identify alternative methods in which complications can be intervened to avoid future problems/errors.
- 2 Review and discuss surgical complications, the associated pathophysiology, and the management therefore, including medico-legal ramifications.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
Kara Lehman, Mzisadari Pontrelli
(215) 531-1570, (215) 662-6157

kara.lehman@pennmedicine.upenn.edu, mzisa@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Michael Acker, MD	Course Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.- FineHeart Paid consultant-Iota Biosciences Paid consultant-BlueRock Therapeutics - 11/12/2024
Wilson Y Szeto, MD	Other Planning Committee Member	Grant or research support-Edwards Lifesciences Grant or research support-Terumo Grant or research support-Medtronic Consulting Fee-Artivion Consulting Fee-Microinterventional device Consulting Fee-Medeaon - 01/08/2025
Christian Bermudez, MD	Other Planning Committee Member	Nothing to disclose - 06/25/2025
Tracy D Andrews, APRN	Co-Director	Nothing to disclose - 07/01/2025
Edward Cantu, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-CSL Behring Grant or research support-Bristol-Myers Squibb (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-United Therapeutics Grant or research support-XVIVO, Inc - 06/30/2025
John J Kelly, MD	Other Planning Committee Member	Nothing to disclose - 06/02/2025
Amit Iyengar, MD	Other Planning Committee Member	Nothing to disclose - 06/16/2025

Marisa Cevasco, MD	Faculty, Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- AbioMed Advisor-AbioMed - 10/08/2024
tiffany Moore, PA-C	Physician Assistant Planner	Nothing to disclose - 08/14/2024
Alexandra Sperry, MD	Other Planning Committee Member	Nothing to disclose - 10/17/2024
Michael Catalano, MD	Other Planning Committee Member	Nothing to disclose - 10/16/2024
Rohan S. Arora, MD	Other Planning Committee Member	Nothing to disclose - 10/01/2024
Mauer Biscotti III, MD	Other Planning Committee Member	Nothing to disclose - 06/01/2025
Matthew Brown, MD	Other Planning Committee Member	Nothing to disclose - 05/31/2025
Omar Toubat, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/02/2025
Max Shin, MD	Other Planning Committee Member	Nothing to disclose - 06/12/2025
Samuel T Kim, MD	Other Planning Committee Member	Nothing to disclose - 08/13/2024
Halil Beqaj, MD, MS	Other Planning Committee Member	Nothing to disclose - 08/14/2024

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected